1. Scrip
  2. >>Therapy Areas

Zymeworks Deal Expands Jazz’s Potential Oncology Presence

 
• By Alaric DeArment

The deal focuses on the HER2-targeting bispecific antibody zanidatamab, in development for multiple solid tumor indications expressing HER2.

Zymeworks and Jazz signed a deal worth up to $1.76bn for the HER2-targeting bispecific antibody zanidatamab • Source: Shutterstock

Zymeworks, Inc. is getting a significant infusion of cash and a commercial partner in a deal with Jazz Pharmaceuticals plc for the HER2-targeted bispecific antibody zanidatamab, while Jazz is gaining a drug that expands the range of targeted solid tumors in its portfolio. But one analyst questioned the size of the deal relative to the therapy’s projected revenue potential.

Jazz and Zymeworks announced the deal on 19 October, whereby Zymeworks will receive $50m up front and a second payment...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.